35998-97-1

Basic information

• Product Name: N,N-diethyl-3,4-dinitroaniline
• CAS NO: 35998-97-1
• Molecular Formula: C₁₀H₁₃N₃O₄
• Molecular Weight: 239.2279
• Mol File: 35998-97-1.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 402.6°C at 760 mmHg
• Flash Point: 197.3°C
• Density: 1.299g/cm³
• Vapor Pressure: 1.09E-06mmHg at 25°C
• Refractive Index: 1.599
• CAS DataBase Reference: N,N-diethyl-3,4-dinitroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-diethyl-3,4-dinitroaniline(35998-97-1)
• EPA Substance Registry System: N,N-diethyl-3,4-dinitroaniline(35998-97-1)

Safety Data

• Hazardous Substances Data: 35998-97-1(Hazardous Substances Data)

Upstream product

• 91-66-7 N,N-diethylaniline 
• 364-53-4 4-fluoro-1,2-dinitro-benzene 
• 109-89-7 diethylamine 
• 7664-93-9 sulfuric acid 
• 7697-37-2 nitric acid 

Downstream Products

• 872266-24-5 N-ethyl-2,3,4,6,N-pentanitro-aniline 
• 861525-95-3 N,N-diethyl-2,4,5-trinitro-aniline 
• 861793-42-2 N,N-diethyl-2,3,4-trinitro-aniline 
• 26886-71-5 N⁴,N⁴-diethylbenzene-1,2,4-triamine 
• 54998-01-5 N¹,N¹-diethyl-4-nitro-m-phenylenediamine 

Relevant articles and documents

Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy

As epigenetic readers, bromodomain and extra-terminal domain (BET) family proteins bind to acetylated-lysine residues in histones and recruit protein complexes to promote transcription initiation and elongation. Inhibition of BET bromodomains by small molecule inhibitors has emerged as a promising therapeutic strategy for cancer. Herein, we describe our efforts toward the discovery of a novel series of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as BET inhibitors. Intensive structural modifications led to the identification of compound 35f as the most active inhibitor of BET BRD4 with selectivity against BET family proteins. Further biological studies revealed that compound 35f can arrest the cell cycle in G0/G1 phase and induce apoptosis via decreasing the expression of c-Myc and other proteins related to cell cycle and apoptosis. More importantly, compound 35f showed favorable pharmacokinetic properties and antitumor efficacy in MV4-11 mouse xenograft model with acceptable tolerability. These results indicated that BET inhibitors could be potentially used to treat hematologic malignancies and some solid tumors.